Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 10, 2008, Pages 5413-5423

  Kapuriya, Naval ^a   Kapuriya, Kalpana ^a   Zhang, Xiuguo ^b   Chou, Ting Chao ^b   Kakadiya, Rajesh ^a   Wu, Yu Tse ^c   Tsai, Tung Hu ^c   Chen, Yu Ting ^a   Lee, Te Chang ^a   Shah, Anamik ^d   Naliapara, Yogesh ^d   Su, Tsann Long ^a  

^a ACADEMIA SINICA   (Taiwan)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d SAURASHTRA UNIVERSITY   (India)

Author keywords

9 Anilinoacridines; Aniline nitrogen mustards; Cytotoxic; DNA alkylating agents

Indexed keywords

1 [4 [BIS(2 CHLOROETHYL)AMINO]PHENYL] 3 [2 METHYL 5 (4 METHYLACRIDIN 9 YLAMINO)PHENYL]UREA; 4 BIS(2 CHLOROETHYL)AMINOPHENYLISOCYANATE; 9 ANILINOACRIDINE DERIVATIVE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE; ISOCYANIC ACID DERIVATIVE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DNA CROSS LINKING; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; REACTION ANALYSIS; XENOGRAFT;

ACRIDINES; AMSACRINE; ANILINE MUSTARD; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MOLECULAR STRUCTURE; RATS; STEREOISOMERISM; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

BRASSICACEAE; MUS MUSCULUS; RATTUS;

EID: 43749104019     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.04.024     Document Type: Article

References (29)

1. Gajski S.R., and William R.M. Chem. Rev. 98 (1998) 2723
2. Denny W.A. Curr. Med. Chem. 8 (2001) 533
3. Suzukake K., Vistica B.P., and Vistica D.T. Biochem. Pharmacol. 32 (1983) 165
4. Rodney M., Carney J.P., Kelley M.R., Glassner B.J., Williams D.A., and Samson L. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 206
5. Kaldor J.M., Day N.E., and Hemminki K. Eur. J. Cancer Clin. Oncol. 24 (1988) 703
6. Gourdie T.A., Valu K.K., Gravatt G.L., Boritzki T.J., Baguley B.C., Wakelin L.P.G., Wilson W.R., Woodgate P.D., and Denny W.A. J. Med. Chem. 33 (1990) 1177
7. Fan J.-Y., Valu K.K., Woodgate P.D., Baguley B.C., and Denny W.A. Anti-Cancer Drug Des. 12 (1997) 181
8. Wyatt M.D., Lee M., and Hartley J.A. Anti-Cancer Drug Des. 12 (1997) 49
9. Bacherikov V.A., Chou T.-C., Dong H.-J., Zhang X., Chen C.-H., Lin Y.-W., Tsai T.-J., Lee R.-Z., Liu L.F., and Su T.-L. Bioorg. Med. Chem. 13 (2005) 3993
10. Su T.-L., Lin Y.-W., Chou T.-C., Zhang X., Bacherikov V.A., Chen C.-H., Liu L.F., and Tsai T.-J. J. Med. Chem. 49 (2006) 3710
11. Springer C.J., Dowell R., Burke P.J., Hadley E., Davies D., Blakey D.C., Melton R.G., and Niculescu-Duvaz I. J. Med. Chem. 38 (1995) 5051
12. Springer C.J., Antoniw P., Bagshawe K.D., Searle F., Bisset G.M.F., and Jarman M. J. Med. Chem. 33 (1990) 677
13. Springer C.J. Drugs Future 18 (1993) 212
14. Jordan A.M., Khan T.H., Malkin H., Helen M.I., and Osborn H.M.I. Bioorg. Med. Chem. 10 (2002) 2625
15. Jordan A.M., Khan T.H., Osborn H.M.I., Photiou A., and Riley P.A. Bioorg. Med. Chem. 7 (1999) 1775
16. Knaggs S., Malkin H., Osborn H.M.I., Williams N.A.O., and Yaqoob P. Org. Biomol. Chem. 3 (2005) 4002
17. Su T.-L., Chou T.-C., Kim J.Y., Huang J.-T., Ciszewska G., Ren W.-Y., Otter G.M., Sirotnak F.M., and Watanabe K.A. J. Med. Chem. 38 (1995) 3226
18. Su T.-L. Curr. Med. Chem. 9 (2002) 1677
19. Chang J.-Y., Lin C.-F., Pan W.-Y., Bacherikov V., Chou T.-C., Chen C.-H., Dong H., Cheng S.-Y., Tsai T.-J., Lin Y.-W., Chen K.-T., Chen L.-T., and Su T.-L. Bioorg. Med. Chem. 11 (2003) 4959
20. Bacherikov V.A., Lin Y.W., Chang J.-Y., Chen C.H., Pan W.-Y., Dong H., Lee R.-Z., Chou T.-C., and Su T.-L. Bioorg. Med. Chem. 13 (2005) 6513
21. Dowell R.I., Springer C.J., Davies D.H., Hadley E.M., Burke P.J., Boyle F.T., Melton R.G., and Connors T.A. J. Med. Chem. 39 (1996) 1100
22. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., and Boyd M.R. Cancer Res. 48 (1988) 4827
23. Skehan P., Storeng R.H., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenny S., and Boyd M.R. J. Natl. Cancer Inst. 82 (1990) 1107
24. Chou T.-C., O'Connor O.A., Tong W.P., Guan Y.-B., Zhang X.-G., Stachel S.J., Lee S., and Danishefsky S.J. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8113
25. Chou, T.-C., Martin, N. ComboSyn, Inc.: Paramus, NJ, 2005.
26. Chou T.-C., and Talalay P. Adv. Enzyme Regul. 22 (1984) 27
27. Chou T.-C. Pharmacol. Rev. 58 (2006) 621
28. Singh N.P., McCoy M.T., Tice R.R., and Schneider E.L. Exp. Cell Res. 175 (1988) 184
29. Friedmann B.J., Caplin M., Savic B., Shah T., Lord C.J., Ashworth A., Hartley J.A., and Hochhauser D. Mol. Cancer Ther. 5 (2006) 209